Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Analyst Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PSNL Stock 12 Month Forecast
Average Price Target
$11.00
▲(25.43% Upside)
| Highest Price Target$12.00 | Average Price Target$11.00 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Craig-Hallum
―
Buy
―
Reiterated
12/01/25
Morgan Stanley
$9→$11
Hold
25.43%
Upside
Reiterated
12/01/25
Lake Street
$11
Buy
25.43%
Upside
Reiterated
11/25/25
Guggenheim
$6→$12
Buy
36.83%
Upside
Reiterated
11/10/25
Needham
$10
Buy
14.03%
Upside
Reiterated
11/10/25
Personalis Secures Medicare Coverage for NeXT Personal MRD Test, Positioning for Growth in Underpenetrated $20 Billion MarketWe note that in a recent study published in the Personal detected 100% of the patients who had breast cancer recurrence (median ~15 months ahead of standard-of-care radiographic imaging), and patients who tested and remained negative with NeXT Personal remained disease-free, highlighting the test's strong sensitivity. This marks the first Medicare-covered MRD indication for NeXT Personal and we view this as a first step toward broader MRD coverage. We note that PSNL has also submitted for Medicare reimbursement in immunotherapy monitoring and lung cancer, and management expects one additional positive Medicare coverage decision before year-end. With Medicare breast cancer coverage in place, we expect PSNL's clinical testing revenue to begin to ramp, and we expect this to reduce its cash burn.
TD Cowen
$11
Buy
25.43%
Upside
Reiterated
11/05/25
BTIG
$8→$6
Buy
-31.58%
Downside
Reiterated
08/06/25
Citi
$8
Buy
-8.78%
Downside
Reiterated
02/27/25
Strong Growth Potential for Personalis Driven by NeXT Personal MRD Test Kit and Strategic CollaborationsValuation and Risks. We maintain our Buy rating on PSNL and our 12-month price target of $8.00 per share. We derive our price target based on the average of two valuation methods: (1) an NPV analysis of projected future revenues through 2030, assuming a 7.5% discount rate and a 0% terminal growth rate; and (2) an EV/sales analysis using a 3x multiple on projected 2030 sales and discounted at 7.5%. The average of our two valuation methods results in a 12-month price target of $8.03 per diluted share which we round up to $8.00.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Craig-Hallum
―
Buy
―
Reiterated
12/01/25
Morgan Stanley
$9→$11
Hold
25.43%
Upside
Reiterated
12/01/25
Lake Street
$11
Buy
25.43%
Upside
Reiterated
11/25/25
Guggenheim
$6→$12
Buy
36.83%
Upside
Reiterated
11/10/25
Needham
$10
Buy
14.03%
Upside
Reiterated
11/10/25
Personalis Secures Medicare Coverage for NeXT Personal MRD Test, Positioning for Growth in Underpenetrated $20 Billion MarketWe note that in a recent study published in the Personal detected 100% of the patients who had breast cancer recurrence (median ~15 months ahead of standard-of-care radiographic imaging), and patients who tested and remained negative with NeXT Personal remained disease-free, highlighting the test's strong sensitivity. This marks the first Medicare-covered MRD indication for NeXT Personal and we view this as a first step toward broader MRD coverage. We note that PSNL has also submitted for Medicare reimbursement in immunotherapy monitoring and lung cancer, and management expects one additional positive Medicare coverage decision before year-end. With Medicare breast cancer coverage in place, we expect PSNL's clinical testing revenue to begin to ramp, and we expect this to reduce its cash burn.
TD Cowen
$11
Buy
25.43%
Upside
Reiterated
11/05/25
BTIG
$8→$6
Buy
-31.58%
Downside
Reiterated
08/06/25
Citi
$8
Buy
-8.78%
Downside
Reiterated
02/27/25
Strong Growth Potential for Personalis Driven by NeXT Personal MRD Test Kit and Strategic CollaborationsValuation and Risks. We maintain our Buy rating on PSNL and our 12-month price target of $8.00 per share. We derive our price target based on the average of two valuation methods: (1) an NPV analysis of projected future revenues through 2030, assuming a 7.5% discount rate and a 0% terminal growth rate; and (2) an EV/sales analysis using a 3x multiple on projected 2030 sales and discounted at 7.5%. The average of our two valuation methods results in a 12-month price target of $8.03 per diluted share which we round up to $8.00.
Best Analysts Covering Personalis
1 Month
xxx
Success Rate
8/15 ratings generated profit
Average Return
+7.11%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +7.11% per trade.
3 Months
xxx
Success Rate
11/15 ratings generated profit
Average Return
+40.92%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +40.92% per trade.
1 Year
Success Rate
15/15 ratings generated profit
Average Return
+102.30%
reiterated a buy rating 19 days ago
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +102.30% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
Average Return
+179.93%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +179.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PSNL Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
5
5
5
2
1
Buy
8
7
4
10
11
Hold
11
10
8
8
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
22
17
20
21
Each month's total comprises the sum of three months' worth of ratings.
PSNL Financial Forecast
PSNL Stock Forecast FAQ
What is PSNL’s average 12-month price target, according to analysts?
Based on analyst ratings, Personalis Inc’s 12-month average price target is 11.00.
What is PSNL’s upside potential, based on the analysts’ average price target?
Personalis Inc has 25.43% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PSNL a Buy, Sell or Hold?
Personalis Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
What is Personalis Inc’s price target?
The average price target for Personalis Inc is 11.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $10.00. The average price target represents 25.43% Increase from the current price of $8.77.
The highest analyst price target is $12.00 ,the lowest forecast is $10.00. The average price target represents 25.43% Increase from the current price of $8.77.
What do analysts say about Personalis Inc?
Personalis Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of PSNL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.